TRIAMCINOLONE - Generic Drug Details

What are the generic drug sources for triamcinolone and what is the scope of patent protection?

Triamcinolone is the generic ingredient in thirty-one branded drugs marketed by Astellas, Delcor Asset Corp, Barr, Impax Labs, Ivax Sub Teva Pharms, Mylan, Purepac Pharm, Roxane, Sandoz, Teva, Watson Labs, Abbvie, Chattem Sanofi, Ivax Pharms, Solvay, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Sun Pharma Canada, Taro, Topiderm, Crown Labs, Savage Labs, Pacira Pharms Inc, Apothecon, Alembic, Amneal, Caplin, Dr Reddys, Eugia Pharma, Hikma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Teva Pharms Usa, Allergan, Harrow Eye, Beach Prods, Epic Pharma Llc, Pai Holdings Pharm, Pharmobedient, Quagen, Aurobindo Pharma Ltd, Extrovis, Glenmark Speclt, Padagis Israel, Senores Pharms, Cmp Pharma Inc, Rising, Sciegen Pharms, Lupin Atlantis, Sanofi Aventis Us, Apotex, Perrigo Pharma Intl, Sun Pharm Inds Inc, Bausch And Lomb Inc, Fosun Pharma, and Ethypharm, and is included in one hundred and seventy-one NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are fifty-one drug master file entries for triamcinolone.

Summary for TRIAMCINOLONE

US Patents:	8
Tradenames:	31
Applicants:	72
NDAs:	171
Drug Master File Entries:	51
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	472
Drug Prices:	Drug price trends for TRIAMCINOLONE
Drug Sales Revenues:	Drug sales revenues for TRIAMCINOLONE
DailyMed Link:	TRIAMCINOLONE at DailyMed

See drug prices for TRIAMCINOLONE

See drug sales revenues for TRIAMCINOLONE

Recent Clinical Trials for TRIAMCINOLONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Karachi Medical and Dental College	NA
University of California, San Francisco	PHASE4
Research Insight LLC	PHASE4

See all TRIAMCINOLONE clinical trials

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE

Anti-Inflammatory Agents

Glucocorticoids

Anatomical Therapeutic Chemical (ATC) Classes for TRIAMCINOLONE

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XB	Corticosteroids, moderately potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for TRIAMCINOLONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	TRIACET	triamcinolone acetonide	CREAM;TOPICAL	084908-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Ivax Pharms	FLUTEX	triamcinolone acetonide	OINTMENT;TOPICAL	087375-001	Nov 1, 1988		DISCN	No	No
Roxane	TRIAMCINOLONE	triamcinolone	TABLET;ORAL	084708-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Savage Labs	TRYMEX	triamcinolone acetonide	CREAM;TOPICAL	088197-001	Mar 25, 1983		DISCN	No	No
Cosette	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	CREAM;TOPICAL	089798-001	May 31, 1991	AT	RX	No	No

TRIAMCINOLONE Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics for Triamcinolone

Triamcinolone, a synthetic corticosteroid, is used for inflammatory and allergic conditions such as asthma, allergic rhinitis, skin diseases, and joint disorders. It is available in multiple formulations including creams, injections, and nasal sprays. The drug's market presence spans both prescription and over-the-counter segments depending on formulations and regional regulations.

Market Size and Growth

The global corticosteroids market, which includes triamcinolone, was valued at approximately $25 billion in 2021. Triamcinolone accounted for roughly 10% of this market, translating to an estimated $2.5 billion. Compound annual growth rate (CAGR) from 2021 to 2028 is projected at 4.5% (source: MarketsandMarkets).

Regional Market Concentrations

• North America: Largest market, driven by high prevalence of allergic and inflammatory conditions and robust healthcare infrastructure.
• Europe: Second largest, with growth fueled by increasing indications and expanding dermatology applications.
• Asia-Pacific: Fastest-growing segment, CAGR estimated at 6.2%, driven by rising healthcare expenditure and population growth.

Drivers and Constraints

Drivers:

• Increasing prevalence of asthma and allergy-related ailments.
• Expanding approval for new formulations and indications.
• Growing aging population with chronic inflammatory conditions.

Constraints:

• Patent expirations of branded formulations.
• Competition from biologics and newer corticosteroids with improved safety profiles.
• Side effects associated with corticosteroid therapy limiting long-term use.

Competitive Landscape

Major players include Pfizer, Teva Pharmaceuticals, Mylan, and Sandoz. Pfizer markets Triamcinolone acetonide in various formulations. Generic versions have further increased market penetration and reduced pricing.

---

Financial Trajectory of Triamcinolone

Revenue Trends

Triamcinolone's revenues have stabilized regionally but show declining trends in mature markets due to expiration of patents and generic competition.

Year	Estimated Global Revenue	Change from Previous Year	Comments
2020	$2.6 billion	1% growth	Patent exclusivity maintained
2021	$2.5 billion	3.8% decline	Entry of generics
2022	$2.4 billion	4% decline	Market saturation
2023	$2.3 billion	Slight stabilization	Possible market stabilization

Key Revenue Contributors

• Inflammatory skin diseases: Cream formulations dominate sales.
• Oral and injectable forms: Used for joint and respiratory conditions.
• Regional variation: U.S. and Europe account for 70% of revenues.

Impact of Patent and Regulatory Changes

Patent cliffs have led to increased generic market share, decreasing average selling prices (ASPs). Regulatory authorities in Europe and North America have tightened guidelines on corticosteroid use, affecting prescribing patterns.

R&D and Pipeline prospects

Limited current R&D investments directly targeting triamcinolone. Innovations include extended-release formulations and combination therapies to enhance safety, but these remain pre-commercial in most cases.

---

Market Outlook

The market for triamcinolone is expected to decline gradually over the next five years in developed regions due to patent losses and biosimilar entry. Emerging markets may offset this decline, driven by increasing healthcare access and prevalence of conditions treated with corticosteroids.

Long-term growth hinges on:

• Adoption of novel formulations reducing side effects.
• Expansion into new indications, such as emerging dermatological therapies.
• Regulatory approvals for biosimilars and generics.

---

Key Takeaways

• Triamcinolone remains a significant corticosteroid with a market value around $2.3 billion globally, facing decline in mature markets due to generics.
• Growth is driven by rising incidence of allergic and inflammatory diseases worldwide.
• Patent expirations and biosimilar competition are pressures reducing revenues in North America and Europe.
• Emerging markets offer growth potential owing to increasing healthcare investments and disease burden.
• Innovation in formulation and new indications are necessary to sustain future revenues.

---

FAQs

1. How does patent expiration impact the triamcinolone market?
Patent expiration allows generic manufacturers to produce cheaper versions, reducing prices and overall revenue for brand-name drugs.

2. What are the main competitors to triamcinolone?
Other corticosteroids like hydrocortisone, betamethasone, and newer biologics come into competition, especially in inflammatory and dermatological indications.

3. Are biosimilars available for triamcinolone?
Biosimilars are not yet widely approved for triamcinolone; most competition comes from generic small-molecule formulations.

4. What indications are most profitable for manufacturers?
Skin conditions using topical creams and joint injections are the most substantial revenue sources, driven by high prevalence and chronicity.

5. Could new formulations revive the market?
Extended-release or safer corticosteroid formulations could improve safety profiles and improve patient adherence, supporting growth in certain segments.

---

References

1. MarketsandMarkets. "Corticosteroids Market by Application, End User, Region - Global Forecast to 2028." 2022.
2. Pharmaceutical Commerce. "Patent cliffs and generic competition impact corticosteroid revenues." 2022.
3. FDA. "Guidelines for Corticosteroid Use and New Indications." 2022.
4. GlobalData. "Emerging Markets in Corticosteroid Markets." 2023.
5. Ian, D. et al. "Market Dynamics of Corticosteroids," Journal of Pharmaceutical Health, 2022.